Compared to matching placebo what was the result of pravastatin 40 mg daily on difference in risk of any of the endpoints?
while thirds of IL-6 showed little discriminative ability in separating risk for nonfatal CVD in unadjusted models (p = 0.13), associations with risk for fatal CVD events, fatal other CV events, or non-CVD mortality were all highly significant (p≤0.0002 for all).